
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Evan Y. Yu, MD, discusses the case and subsequent palliative treatment plan for a patient with metastatic castration-resistant prostate cancer.
Case: A 66-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
Initial presentation
Clinical workup
Treatment and Follow-Up






